Key facts
- This page summarizes ALEXANDRIA REAL ESTATE EQUITIES, INC.'s Form 4 filing for Applied Therapeutics Inc. (APLT).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Oct 2023, 19:17.
ALEXANDRIA REAL ESTATE EQUITIES, INC. - 12 Oct 2023 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- APLT
- Reported as of
- 12 Oct 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Oct 2023, 19:17:08 UTC
- Prior SEC filing
- 26 Jul 2023
- Next SEC filing
- 02 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
-
ALEXANDRIA EQUITIES NO. 7, LLC By: ARE-Special Services, LLC, managing member By: ALEXANDRIA REAL ESTATE EQUITIES, L.P., managing member By: ARE-QRS CORP., general partner By: /s/ Marc E. Binda, Chief Financial...
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ALEXANDRIA REAL ESTATE EQUITIES, INC. filed Form 4 for Applied Therapeutics Inc. (APLT) on 16 Oct 2023.
Change
- Previous filing in this sequence was filed on 26 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLT
transaction
Common Stock
Other
- Transaction value
- Shares
- +1,600,000
- Change %
- +35%
- Price
- Shares after
- 6,155,077
- Date
- 12 Oct 2023
- Ownership
- By subsidiary
- Footnotes
- F1, F2
APLT
transaction
Common Stock
Other
- Transaction value
- Shares
- -1,600,000
- Change %
- -67%
- Price
- Shares after
- 778,977
- Date
- 12 Oct 2023
- Ownership
- By subsidiary
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLT
transaction
Derivative
Pre-Funded Warrant
Other
- Transaction value
- Shares
- +615,000
- Change %
- +69%
- Price
- Shares after
- 1,500,000
- Date
- 12 Oct 2023
- Ownership
- By subidiary
- Underlying class
- Common Stock
- Underlying amount
- 615,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F4
APLT
transaction
Derivative
Pre-Funded Warrant
Other
- Transaction value
- Shares
- -615,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Oct 2023
- Ownership
- By subsidiary
- Underlying class
- Common Stock
- Underlying amount
- 0
- Exercise price
- $0.000100
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These shares have been transferred from Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc. to Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc.
Footnote F2
These securities are held directly by Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc.
Footnote F3
These securities are held directly by Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc.
Footnote F4
The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise.